Rift Valley Fever Innovation Lab: Rift Valley fever vaccine animal testing data at Sante Animale MCI in Mohammedia, Morocco

The objective of this study was to evaluate the safety and immunogenicity of a live, attenuated recombinant RVF arMP-12ΔNSm21/384 nucleotide deletion vaccine candidate in domestic ruminants. . The immunogenicity of 2 doses of 104 and 105 Tissue Culture Infectious Doses50% (TCID50) of the vaccine was assessed in of 2 groups of 10 sheep, 2 groups of 10 goats, and doses of 105 and 106 TCID50 were used to vaccinate 2 groups of 10 calves. The results showed that the immunogenicity among sheep, goats and cattle indicated that doses of 104 - 106 TCID50 elicited detectable antibody by day 7 post-vaccination and antibody titers that ranged from 1:14 to 1:305 on day 14 PV with sustained titers through day 28 PV. Overall, these findings indicated that the RVF arMP-12ΔNSm21/384 vaccine is a promising candidate for the prevention of RVF among domestic ruminants.